Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gemcitabine and R115777 (Tipifarnib) Combination Therapy for Metastatic Breast Cancer.

Trial Profile

Gemcitabine and R115777 (Tipifarnib) Combination Therapy for Metastatic Breast Cancer.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Jan 2018

At a glance

  • Drugs Gemcitabine (Primary) ; Tipifarnib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2018 Primary endpoint (Objective response rate (ORR)) has not been met, as per results published in the Investigational New Drugs.
    • 27 Jan 2018 Results assessing efficacy of combination of tipifarnib and gemcitabine published in the Investigational New Drugs.
    • 01 Jul 2013 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top